HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Maekawa, M. Articles by Kanno, T. Search for Related Content PubMed PubMed Citation Articles by Maekawa, M. Articles by Kanno, T. Related Collections Molecular Diagnostics and Genetics Proteomics and Protein Markers Cancer Diagnostics (since 2002)

Promoter Hypermethylation in Cancer Silences LDHB, Eliminating Lactate Dehydrogenase Isoenzymes 1-4

¹ Department of Laboratory Medicine and

² First Department of Pathology, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan

³ Oncogene Research Unit/Cancer Prevention Unit, Tochigi Cancer Center Research Institute, Utsunomiya 320-0834, Japan

^aauthor for correspondence: fax 81-53-435-2794, e-mail mmaekawa@hama-med.ac.jp

The first 300 words of the full text of this article appear below.

Lactate dehydrogenase (LD; EC 1.1.1.27) isoenzymes are formed by the random combination of two different subunits encoded by two structurally distinct genes, LDHA and LDHB (1). Expression of mammalian LDHA and LDHB is regulated during development and is tissue specific (2)(3); therefore, alterations in the serum LD isoenzyme pattern serve as indicators of pathologic involvement and cancer development (3). In cancer patients, LD isoenzymes originate primarily from tumor tissues and partly from healthy tissues damaged by tumor expansion and invasion. Different phenotypes may originate from expression regulation by other regulatory genes and by the alteration of LDHA or LDHB caused by mutation; chromosomal deletion; duplication, or increase of copy number; and promoter methylation. The increase in LD1 correlates with the total copy number of the short arm of chromosome 12 in tumor cells (4). Recently, we found a high proportion of LD1 in a patient with retinoblastoma. The unique LD isoenzyme pattern was attributable to transcriptional silencing by promoter hypermethylation of LDHA (5).

In mammals, DNA methylation usually occurs at CpG dinucleotides, which are cytosines located 5' of guanines. Methylation is known to play a role in regulating gene expression during cell development, X chromosome inactivation, genomic imprinting, and carcinogenesis (6)(7). In neoplastic cells, some CpG islands in the promoter region that are usually unmethylated become aberrantly methylated, and this leads to transcriptional silencing. Therefore, an epigenetic event is thought to be one mechanism for the inactivation of tumor suppressor genes (8).

Human LDHB has a CpG-rich region in its promoter that is similar to that of human LDHA and LDHC (9). We found that five cancer cell lines had only LDHA mRNA (10). Most gastrointestinal cancer patients . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				M. Shamay, A. Krithivas, J. Zhang, and S. D. Hayward Recruitment of the de novo DNA methyltransferase Dnmt3a by Kaposi's sarcoma-associated herpesvirus LANA PNAS, September 26, 2006; 103(39): 14554 - 14559. [Abstract] [Full Text] [PDF]

				J. Ishikawa, T. Taniguchi, H. Higashi, K. Miura, K. Suzuki, A. Takeshita, and M. Maekawa High Lactate Dehydrogenase Isoenzyme 1 in a Patient with Malignant Germ Cell Tumor Is Attributable to Aberrant Methylation of the LDHA Gene Clin. Chem., October 1, 2004; 50(10): 1826 - 1828. [Full Text] [PDF]